scholarly journals R-COMP VS R-CHOP AS FIRST-LINE THERAPY FOR DIFFUSE LARGE B-CELL LYMPHOMA IN PATIENTS OLDER THAN 60 YEARS: RESULTS FROM A RANDOMIZED PHASE 2 STUDY FROM THE SPANISH GELTAMO GROUP

2017 ◽  
Vol 35 ◽  
pp. 186-187
Author(s):  
J. Sancho ◽  
F. Gual ◽  
R. Fernández-Álvarez ◽  
E. González-García ◽  
C. Grande ◽  
...  
Keyword(s):  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Phase 2 ◽  
First Line ◽  
First Line Therapy ◽  
Large B Cell Lymphoma ◽  
Line Therapy ◽  
Phase 2 Study ◽  
Randomized Phase 2 ◽  
Large B Cell

scholarly journals R‐COMP versus R‐CHOP as first‐line therapy for diffuse large B‐cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group

2021 ◽  
Author(s):  
Juan‐Manuel Sancho ◽  
Rubén Fernández‐Alvarez ◽  
Francisco Gual‐Capllonch ◽  
Esther González‐García ◽  
Carlos Grande ◽  
...  
Keyword(s):  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Phase 2 ◽  
First Line ◽  
First Line Therapy ◽  
Large B Cell Lymphoma ◽  
Line Therapy ◽  
Phase 2 Study ◽  
Randomized Phase 2 ◽  
Large B Cell

scholarly journals Prognostic significance of infectious episodes occurring during first‐line therapy for diffuse large B‐cell lymphoma ‐ A nationwide cohort study

2020 ◽  
Vol 38 (3) ◽  
pp. 318-325
Author(s):  
Michael R. Clausen ◽  
Sinna P. Ulrichsen ◽  
Maja B. Juul ◽  
Christian B. Poulsen ◽  
Brian Iversen ◽  
...  
Keyword(s):  
Cohort Study ◽  
B Cell ◽  
Cell Lymphoma ◽  
Prognostic Significance ◽  
B Cell Lymphoma ◽  
First Line ◽  
First Line Therapy ◽  
Large B Cell Lymphoma ◽  
Line Therapy ◽  
Large B Cell
Sign in / Sign up

Export Citation Format

Share Document